Roivant Advances Mosliciguat to Phase 3 After Strongest PVR Reduction Yet in PH-ILD
Mosliciguat cut PVR 56.3% vs placebo in Phase 2 PH-ILD, improved 6-minute walk, and advanced to Phase 3. Shares jumped on the data.
/ 491 items
#XY Event-Driven Stocks↓
Novartis, Ionis Heart Drug Misses Phase 3 Goal Despite Cutting Lp(a)
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.
HUTCHMED and GSK Sign Deal for Dual-Targeted KRAS-EGFR Cancer Drug
HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.
Ultragenyx Stock Plunges After Phase 3 Failure in Angelman Syndrome
GTX-102 failed Phase 3 in Angelman syndrome. Ultragenyx will review the program and reduce expenses.
Definitive Healthcare Names Clay Ritchey CEO as Advent Offers $1.02 Take-Private Bid
A special committee is reviewing the offer.
TScan Pivots to In-Body T-Cell Therapy for Solid Tumors, Cuts 75% of Staff
TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.